Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)

Trial Profile

Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Prasugrel (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Acronyms ELDERLY-ACS2
  • Most Recent Events

    • 23 Feb 2018 Status changed from recruiting to discontinued due to futility for efficacy, according to the results published in the Circulation
    • 19 Feb 2018 Primary endpoint (The composite of all-cause mortality, myocardial infarction (MI), disabling stroke and re-hospitalization for cardiovascular causes or bleeding within one year) has not been met, according to the results published in the Circulation
    • 19 Feb 2018 Results of the planned interim analysis, published in the Circulation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top